tizaro tirzepatide injection (Trizapatide) Pre-Filled Syringe Tizaro is a brand of
Description
And sometimes uncomfortable
This is an enormous addressable patient population that has either never started injectable therapy or discontinued it
Treatment should be discontinued if patients do not lose at least 5% of their initial body weight after 12 weeks at the maintenance dose
Final note (and my stake in it) This drug class changes every few months: new trial results, new shortages, new coverage rules, new options
Both medicines were initially developed to help manage type 2 diabetes, but clinical research quickly revealed substantial weight loss benefits
